

2025 Q1 Muscular Dystrophy Community Newsletter

This newsletter is intended for U.S. residents. Individuals should always discuss questions about their medical care with their medical care provider.

OCANYON

Positive topline results from the CANYON Phase 2 trial of sevasemten in individuals living with Becker muscular dystrophy were announced in December 2024

We are pleased to share that the trial met the primary endpoint of reduction in circulating levels of creatine kinase, a biomarker associated with skeletal muscle damage. The North Star Ambulatory Assessment, the key secondary endpoint of function, showed a trend toward improvement over time in the **sevasemten**-treated group. **Sevasemten** was well-tolerated, and no new safety concerns were observed in either the adult or adolescent populations. Notably, 99% of eligible Becker participants from **CANYON** and other sevasemten trials chose to enroll in **MESA**, the ongoing open label extension trial.

Click here to read the full press release



GRAND CANYON is fully recruited and overenrolled with 175 participants!

The **GRAND CANYON (NCT05291091)** study for Becker muscular dystrophy has completed enrollment and is now ongoing at ~50 sites across 12 countries including the United States, Australia, Belgium, Denmark, France, Germany, Italy, Israel, Netherlands, New Zealand, Spain and the United Kingdom. Study participation will span 18 months and is expected to conclude by the second half of 2026.

<u>Click here</u> or go to <u>clinicaltrials.gov/study/NCT05291091</u> to learn more





LYNX and FOX Phase 2 trials in boys with Duchenne

LYNX is an ongoing multi-center, dose-finding Phase 2 trial to evaluate the effect of **sevasemten** on safety, biomarkers of muscle damage and function in children with Duchenne treated with oral, once-daily **sevasemten**.

FOX is an ongoing Phase 2 placebo-controlled trial to assess the effects of sevasemten in children and adolescents with Duchenne who have been previously treated with gene therapy.

Edgewise expects to report data from **LYNX** and **FOX** as well as its future development plans in the first half of 2025.

For more information, go to clinicaltrials.gov to learn more about **LYNX (NCT05540860)** and **FOX (NCT0610087)** or <u>click here</u> to read the Edgewise March 3rd press release covering program updates.

We Want to Hear from You!

Please take a few moments to complete our 5 question survey to help us improve our newsletter!

What is your connection to the muscular dystrophy community?

- A. I or my loved one live with Becker muscular dystrophy
- B. I or my loved one live with Duchenne muscular dystrophy
- C. I or my loved one lives with a different type of muscular dystrophy
- D. I am a medical professional or researcher
- E. I work for a patient advocacy organization
- F. I am an investor in muscular dystrophy trials
- G. Other

SUBMIT YOUR ANSWER HERE